Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Go back to Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM| (NASDAQ: ORGO) | Delayed: 2.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.43 | 52 Week High | $ | |||
| Open | $2.42 | 52 Week Low | $ | |||
| Day High | $2.45 | P/E | N/A | |||
| Day Low | $2.32 | EPS | $ | |||
| Volume | 1,013,102 | |||||
